Impact of CNS Diseases on Drug Delivery to Brain Extracellular and Intracellular Target Sites in Human: A “WHAT-IF” Simulation Study

Mohammed A. A. Saleh and Elizabeth C. M. de Lange

Division of Systems Biomedicine and Pharmacology, Leiden Academic Center for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands; m.a.a.e.w.saleh@lacdr.leidenuniv.nl
* Correspondence: ecmdelange@lacdr.leidenuniv.nl

Abstract: The blood–brain barrier (BBB) is equipped with unique physical and functional processes that control central nervous system (CNS) drug transport and the resulting concentration–time profiles (PK). In CNS diseases, the altered BBB and CNS pathophysiology may affect the CNS PK at the drug target sites in the brain extracellular fluid (brainECF) and intracellular fluid (brainICF) that may result in changes in CNS drug effects. Here, we used our human CNS physiologically-based PK model (LeiCNS-PK3.0) to investigate the impact of altered cerebral blood flow (CBF), tight junction paracellular pore radius (para_radius), brainECF volume, and pH of brainECF (pHECF) and of brainICF (pHICF) on brainECF and brainICF PK for 46 small drugs with distinct physicochemical properties. LeiCNS-PK3.0 simulations showed a drug-dependent effect of the pathophysiological changes on the rate and extent of BBB transport and on brainECF and brainICF PK. Altered para_radius, pHECF, and pHICF affected both the rate and extent of BBB drug transport, whereas changes in CBF and brainECF volume modestly affected the rate of BBB drug transport. While the focus is often on BBB paracellular and active transport processes, this study indicates that also changes in pH should be considered for their important implications on brainECF and brainICF target site PK.

Keywords: blood–brain barrier; passive transport; CNS diseases; brain pharmacokinetics

1. Introduction

Both the rate and extent of central nervous system (CNS) unbound drug transport determine CNS concentration–time profiles of the unbound drug (PK) [1]. PK at the CNS target sites in the brain extracellular fluid (brainECF) and brain intracellular fluid (brainICF) is a function of plasma PK, drug transport across the blood–brain barrier (BBB), and intra-brain distribution. Such PK processes result from the combination of the drug physicochemical properties and the physiological characteristics of the CNS [2,3].

The BBB lies at the brain microvessels, including brain capillaries and their direct surroundings [2]. The BBB has physical properties that reduce passive drug transport across the BBB for hydrophilic and large molecules, i.e., by the presence of the tight junctions between the brain microvascular endothelial cells. In addition, pericytes and astrocyte end feet ensure a complete coverage of the brain microvascular endothelial cells, while the basement membrane surrounds the endothelial cells and pericytes, separating them from each other and from the astrocytes end feet. All together, these cells ensure the physical integrity of the BBB against the foreign plasma molecules. The BBB also has active efflux and influx transporters, pinocytosis, transcytosis, and metabolic enzymes, which are all powered with energy supplied by the large mitochondrial count. The brain tissue composition and active cellular membrane transporters further determine the unbound drug PK in the different brain compartments, while different pH values of the CNS compartments govern, for acids and bases, the extent of ionization [2].
CNS disease pathophysiology may result in altered (unbound) brain PK, as has been shown, for example, for traumatic brain injury [4,5], epilepsy [6], and brain tumors [7]. The brain_ECF and brain_ICF unbound PK govern the CNS drug effects; therefore, understanding the impact of pathophysiological changes associated with CNS diseases on brain PK target sites is indispensable.

While being a very important parameter, \( K_{puu, BBB} \) is a measure for the extent (at equilibrium) but not the rate of drug transport. However, for drug effects, also the profile of concentrations seems of importance [8], i.e., having the right concentration, for the right duration, at the right site. Therefore, CNS drug development should consider the effect of both the rate and extent of BBB drug transport and of intra-brain distribution processes on the target site PK, and as indicated above, these processes may be influenced in CNS disease conditions.

Physiologically-based pharmacokinetic (PBPK) modeling [9] has provided important insights in what governs PK at different CNS sites in health [10] and in disease [11]. PBPK models use a system of ordinary differential equations to predict the rate of change of drug concentration in each physiological compartment. Importantly, PBPK models are mechanistic and explicitly distinguish between physiological body compartment characteristics (such as tissue volume, blood flow, etc.) and drug properties (such as molecular weight, lipophilicity, \( pK_a \), etc.). Body organs and tissues are mathematically represented as compartments with their physiological volumes, and these are connected to the central blood circulation by their physiological blood flows. Physiological processes involved in drug transport and disposition such as active transport, metabolism, tissue non-specific binding, etc. are mechanistically included. Given their mechanistic nature, PBPK models allow the translation between species and between populations and the exploration of different virtual scenarios, i.e., what-if scenarios.

The “Leiden CNS PBPK predictor v3.0” or LeiCNS-PK3.0 (Figure 1 and Figure S1 in Supplementary Materials) is a CNS PBPK model that adequately predicts the PK of small drug molecules in the CNS of rats and humans on the basis of exclusively plasma PK, drug physicochemical, CNS physiological, and in vitro information [10,12,13]. The LeiCNS-PK3.0 model accounts for the different CNS physiological compartments such as the brain microvasculature, brain_ICF and brain_ECF, lysosomes, and cerebrospinal fluid (CSF) compartments (such as lateral ventricles, third and fourth ventricles, cisterna magna, and subarachnoid space, including the lumbar CSF region). Different drug transport modes within the CNS are represented including drug transport by paracellular, transcellular, and active transport across the BBB and blood–CSF barrier (BCSFB) and by bulk fluid flow from the brain_ECF along the CSF compartments back to the plasma. Moreover, the physiological processes that affect intra-brain unbound drug distribution are accounted for, such as brain tissue non-specific binding and the effect of CNS pH on drug ionization.

In general, changes in BBB properties and CNS physiology are common in CNS diseases, as well as in aging or other conditions, but the impact of some of these processes is often overlooked when investigating brain PK in such conditions. These include brain_ECF volume, of which the fraction is doubled during sleep and anesthesia [14] and declines with aging [15]; the BBB tight junctions’ paracellular pore radius (\( para_{radius} \)) that increases for example in Alzheimer’s disease [16], with aging [17], and in traumatic brain injury [18]; CBF that declines for example in Alzheimer’s disease [19], with aging [20], and anesthesia [21]; and pH_ECF/ICF that declines for example in traumatic brain injury [22], brain ischemia [23,24], and with aging [25].

In this paper, we use LeiCNS-PK3.0 to explore the effect of the pathophysiological changes of: CBF, \( para_{radius} \), brain_ECF volume, pH_ECF, and pH_ICF on BBB transport and intra-brain distribution of 46 small drugs of different physicochemical properties.
2. Materials and Methods

2.1. LeiCNS-PK3.0 Model

This simulation study was performed using LeiCNS-PK3.0 (Figure 1 and Figure S1 in Supplementary Materials) and human CNS physiological parameters (Table 1) [12]. A virtual one-compartment plasma PK model was used as input to the CNS model, with plasma clearance of 297 L/h and a central compartment volume of 108 L. The drug dose was 1 g, which was administered as intravenous infusion over 15 min. The fixed plasma PK model and dosing regimen were used for all investigated drugs, thus solely focusing on the impact of CNS parameters changes on brain ECF and brain ICF PK. More information on the model buildup and the associated equations can be found at [10,12,13].

2.2. Drug Parameters

The physicochemical properties of the 46 small drugs (Table 2 and Table S1) in this study were available from the Drugbank database release version 5.1.7 (go.drugbank.com) [26]. These drugs have distinct physicochemical properties such as molecular weight (Mwt: 150–500 g/mol), lipophilicity (logP: −3.7–4.3), acid/base ionization constants (pKₐ: 3–16/pKₐ: −9–10) and different affinities to active transporters. We included calculated pKₐ/p values from CHEMAXON [27] and included calculated lipophilicity from the ALOGPS method [28], unless experimental octanol–water portioning values were reported.
Table 1. Human CNS physiological parameters used in LeiCNS-PK3.0.

| Parameter                                      | Value Range          | Reference |
|------------------------------------------------|----------------------|-----------|
| **Volumes (mL)**                               |                      |           |
| Total brain                                    | 1250                 | [47–50]   |
| Brain extracellular fluid (brainECF)           | 253 🅣                 | [51–55]   |
| Brain intracellular fluid (brainICF)           | 1000 calc             |           |
| Brain cell lysosomes (VLYS)                    | 12.5 🅡               | [56]      |
| Brain microvasculature                         | 45 🅢                 | [53,57,58]|
| Lateral ventricles                             | 20                   | [59–63]   |
| 3rd and 4th ventricles                         | 3                    | [61,62]   |
| Cisterna magna                                 | 1                    | [64]      |
| Subarachnoid space                             | 116                  | [65–67]   |
| **Flows (mL/min)**                             |                      |           |
| Cerebral blood flow (CBF)                      | 689                  | [68–70]   |
| Brain ECF bulk flow                            | 0.2 🅣                | [71]      |
| CSF flow                                       | 0.42                 | [67,72–75]|
| **Surface areas (cm²)**                        |                      |           |
| Blood–brain barrier (SA_{BBB})                 | 150,000              | [76–84]   |
| Blood CSF barrier (SA_{BCSFB})                 | 15,000 🅤              | [85,86]   |
| Brain cell membrane (SA_{BCM})                 | 2,666,520 🅥           | [87,88]   |
| Lysosomes membrane                             | 1,980,260 🅦           | [89–93]   |
| **Width (µm)**                                 |                      |           |
| Blood brain barrier                            | 0.5                  | [81,94]   |
| Blood CSF barrier                              | 0.2–0.4              |           |
| **Number**                                     |                      |           |
| Total brain cells (N_{br,cells})               | 1.71 × 10¹¹ 🅦         | [87,88]   |
| **Paracellular pore radius (µm)**              |                      |           |
| Blood–brain barrier (paradadius)               | 0.0007                | [10,13,95,96] |
| Blood CSF barrier                              | 0.0027                | [10,13,95] |
| **Effective surface area (%)**                 |                      |           |
| BBB Transcellular transport                    | 99.8                 | [13,97,98]|
| BCSFB Transcellular transport                  | 99.8                 |           |
| BBB paracellular transport                     | 0.004 🅩             | [10,95]   |
| BCSFB paracellular transport                   | 0.016 🅩              |           |
| **pH**                                         |                      |           |
| Plasma and brain MV                            | 7.4                  | [99]      |
| Brain extracellular fluid (pH_{ECF})           | 7.3                  | [100]     |
| Cerebrospinal fluid                            | 7.3                  | [101]     |
| Brain cells (pH_{ICF})                         | 7                    | [100]     |
| Brain cell lysosomes                           | 5                    | [100]     |

1. Volume ratio of brainECF:brainICF is 1:4. 2. Calculated as 1.25% (1/80) of brainICF volume; based on liver lysosomes. 3. Calculated as 3.67% of total brain volume. 4. Assumed as 50% of CSF bulk flow. 5. SA_{BCSFB} = 0.1 * SA_{BBB}. SA_{BCSFB} at LV (and TFV) is assumed 50% of SA_{BCSFB}. 6. SA_{BCM} = SA_{cell} * N_{br,cells}. Radius br,cell was calculated with brainICF volume and N_{br,cells}, assuming spherical cells. 7. Based on VLYS and mean radius of lysosomes in monkey kidney, rat kidney, and rat neuronal cell (0.1875 µm). 8. Based on 1500 gm brain. 9. Based on an endothelial cell perimeter of 17 µm.

Active transport across the BBB was described using Kp_{uu, BBB} values (Table 2 and Table S1), which were calculated from rat microdialysis plasma and brainECF drug concentrations [12,29–31]. Then, these were translated to predict human BBB active transport as described in [10], taking into consideration the interspecies difference in protein expression [32–36] of the four main BBB active transporters: P-glycoprotein (p-gp), multi-drug-
resistant protein-4 (MRP4), breast cancer resistance protein (BCRP), and organic anionic transporter 3 (OAT3). The protein expression of other relevant transporters at the BBB such as MRP1 was assumed the same in rats and humans, due to the absence of quantitative information on the difference of protein expression in rats and in humans [32–37]. Information on drugs affinity to a certain transporter was available from Drugbank [26]. The factors used for the rat-to-human translation are summarized in Table S2. Differences in transporters functionality, which is distinct of expression [38], in rats and humans [39–41] were not accounted for. This interspecies difference is not attributed to the transporter per se, but rather to the combination of the drug and the transporter. Given both the scarcity of transporter functionality information in the literature and the goal of the current study, rat-to-human translation was based on differences in expression only.

\[ K_{puu,BBB}^{uu} \]

\[ K_{puu,cell}^{uu} \]

2.3. Selection of Pathophysiological Parameters Values

The CNS parameters investigated in this study were CBF, para-radius, BrainECF volume, pHECF, and pHICF. The changes in the parameters values were selected to reflect their values in CNS diseases. Parameters were changed based on literature values as follows: CBF by 70% [42] and 150% [21]; para-radius by 50% and 500% [43]; brainECF volume by 70% and 150% [14,15]; pHECF to 5 and 8 [23]; and pHICF to 6 and 7.6 [24,44].

2.4. LeiCNS-PK3.0 Simulations and Data Analysis

LeiCNS-PK3.0 simulations were observed over 600 min for all drugs. For low transcellular permeability drugs such as methotrexate and atenolol, brainICF PK were incomplete, i.e., it had not reached C\(_{\text{max}}\) after 600 min, and the observation time was extended to 20,000 min (results not shown). LeiCNS-PK3.0 simulations were performed using RxODE version 0.9.2-0 [45] using LSODA (Livermore Solver for Ordinary Differential Equations) Fortran package and R version 4.0.3 [46].

Table 2. Physicochemical properties, active transporters affinities, and BBB transport clearances of selected drugs.

| Drug       | Mwt   | logP | Drug Ion Class | pKa | pKb | K\(_{\text{puu,ECF}}\) | K\(_{\text{puu,LV}}\) | K\(_{\text{puu,CM}}\) | BCRP | p-gp | OAT3 | MRP4 | CL\(_{P}\) | CL\(_{T,ef}\) | CL\(_{T,in}\) | K\(_{puu,BBB}\) | K\(_{puu,cell}\) |
|------------|-------|------|----------------|-----|-----|-----------------|-----------------|----------------|------|------|------|------|--------|--------|--------|----------------|----------------|
| Caffeine   | 194.2 | −0.07| Neutral        | NA  | NA  | 0.06 | 0.051           | 0.051            | X               | -    | -    | -    | -    | 40.9   | 4.28   | 2.38   | 0.96            | 0.96            |
| Cephalexin | 347.4 | 0.65 | Zwitterion     | 5.26| 7.23| 0.051| 0.051           | 0.051            | X                | -    | -    | -    | -    | 37.4   | 2736   | <0.01  | 0.96            | 0.96            |
| Codeine    | 269.4 | 1.39 | Base           | 12.9| 9.19| 1.1  | 1.1             |                   | -                | -    | -    | -    | -    | 40.1   | 0.71   | 0.89   | 0.96            | 0.96            |
| Gabapentin | 299.4 | 1.25 | Zwitterion     | 4.63| 9.91| 0.133| 0.133           | 0.133            | X                | X    | -    | -    | -    | 51.9   | 347    | <0.01  | 0.96            | 0.96            |
| Captopril  | 270.2 | 3.04 | Acid           | 6.55| 9.12| 0.222| 0.222           | 0.222            | X                | X    | -    | -    | -    | 42.5   | 3557   | 245    | 0.96            | 0.96            |
| Levitracetam| 170.2| −0.64| Neutral        | 16.1| 1.6 | 0.311| 0.311           | 0.311            | X                | -    | X    | -    | -    | 52.0   | 3.75   | 0.49   | 0.96            | 0.96            |
| Morphine   | 285.3 | 0.67 | Base           | 10.3| 9.12| 0.91 | 0.91            | 0.91             | -                | X    | -    | -    | -    | 41.0   | 30.2   | 0.34   | 0.96            | 0.96            |
| Thiopeptol | 242.5 | 2.85 | Acid           | 7.2 | −3  | 0.91 | 0.91            | 0.91             | -                | -    | -    | -    | -    | 44.2   | 569    | 508    | 0.96            | 0.96            |

1 [29]; 2 [12]; Mwt: molecular weight (g/mol); logP: octanol–water partition coefficient; pKa: acid dissociation coefficient; pKb: base dissociation coefficient; CL\(_{T,ef}\): transcellular efflux clearance (in mL/min) at BBB; CL\(_{T,in}\): transcellular influx clearance (in mL/min) at BBB; CL\(_{p}\): paracellular passive BBB clearance (in mL/min); X: active transporter substrate; p-gp: P-glycoprotein, MRP4: multi-drug-resistant protein-4, BCRP: breast cancer resistance protein, OAT3: organic anionic transporter-3. CL\(_{T,ef}\), CL\(_{T,in}\), and CL\(_{p}\) are calculated as described in [12,13].

LeiCNS-PK3.0 simulation results were evaluated by comparing the different PK at brainECF and brainICF of different parameters values. In addition, heatmaps were generated to reflect the magnitude of change of C\(_{\text{max}}\), T\(_{\text{max}}\), AUC\(_{0–T}\), K\(_{puu,BBB}\), and K\(_{puu,cell}\). AUCs were calculated using the R package PKNCA version 0.9.4. K\(_{puu,BBB}\) and K\(_{puu,cell}\) were calculated as follows [1]:

\[ K_{puu,BBB} = \frac{AUC_{0–\infty,ECF}}{AUC_{0–\infty,MV}} \]

\[ K_{puu,cell} = \frac{AUC_{0–\infty,ICF}}{AUC_{0–\infty,ECF}} \]
For $\text{AUC}_{0-\infty}$, the elimination rate constant was calculated from the terminal elimination phase and was used to extrapolate the concentration–time curve to time infinity.

Two-fold change was calculated to reflect the effect of changing one parameter on PK parameters; a value of 1 reflects a two-fold change.

$$\text{Two – fold change} = \log_2 \left( \frac{\text{PK.params}_{\Delta=x}}{\text{PK.params}_{\Delta=1}} \right)$$

where $\text{PK.params}_{\Delta=x}$ and $\text{PK.params}_{\Delta=1}$ represent the calculated PK parameters ($C_{\text{max}}$, $T_{\text{max}}$, $\text{AUC}_{0-T}$, $K_{\text{puu,BBB}}$, and $K_{\text{puu,cell}}$) at $x$-fold altered and physiological CNS parameters, respectively.

3. Results

The simulated impact of pathophysiological changes of CBF, $\text{para}_{\text{radius}}$, brain ECF volume, pH$_{\text{ECF}}$, and pH$_{\text{ICF}}$ on PK at brain ECF and brain ICF are displayed for selected drugs in Figure 2 and for all drugs in Figure S2. The associated heatmaps, Figure 3 and Figure S3, reflect the changes in the BBB drug transport rate via $C_{\text{max}}$, and $T_{\text{max}}$ and extent via $\text{AUC}_{0-T}$, $K_{\text{puu,BBB}}$, and $K_{\text{puu,cell}}$. As plasma PK was fixed, any role of plasma in the observed changes is eliminated. The changes of CBF and brain ECF volume affected the rate but not the extent of BBB drug transport, whereas changes in pH$_{\text{ECF}}$, pH$_{\text{ICF}}$, and $\text{para}_{\text{radius}}$ affected both the rate and extent of BBB drug transport.

3.1. Increased Passive Transport via Widened $\text{Para}_{\text{radius}}$

Figures 2 and 3 (2nd column) demonstrate that the impact of a changed $\text{para}_{\text{radius}}$ on BBB drug passive transport varied according to the drug lipophilicity, ionization at physiological pH, and affinity to active transporters. Of interest, a five-fold increase in $\text{para}_{\text{radius}}$ resulted in a decrease in the extent of BBB transport of risperidone, paliperidone, and omeprazole, as demonstrated by a decrease in $\text{AUC}_{0-T,\text{ECF}}$ and in $K_{\text{puu,BBB}}$.

3.2. pH$_{\text{ECF}}$ and pH$_{\text{ICF}}$ are Key Factors of Drug Distribution in Brain ECF and Brain ICF

Figures 2 and 3 (4th and 5th columns) show the influence of pH changes on the rate and extent of drug transport across the BBB and across the brain cell membranes. A pH increase in a given compartment generally resulted in a faster rate and increased the extent of acidic drug transport and a slower rate and decreased the extent of the basic drug transport into that compartment, and vice versa. The rate and extent of drug transport in the adjacent compartment were affected in an inverse fashion. For amphoteric drugs, the effect of pH on their transport rate and extent was relative to the ionization constants of their strongest acidic and basic groups. As expected, pH changes had no effect on drugs that are neutral at the physiological pH range.

3.3. Brain ECF Volume and CBF Have a Very Modest Effect on Rate of BBB Drug Transport

Figure 3 (1st and 3rd columns) display only a $T_{\text{max}}$ increase of $<50\%$ associated with a 50% increase of brain ECF volume, while a slight $T_{\text{max}}$ decrease of $<25\%$ was noticed with a 30% decrease of brain ECF volume. With regard to CBF, a 30%-delay resulted in a $<50\%$-decrease of $T_{\text{max}}$, whereas a 50%-delay resulted in a $<25\%$-earlier $T_{\text{max}}$. These effects were associated with neutral drugs of relatively higher net BBB influx.
Figure 2. Simulated concentration–time profiles of selected drugs at physiological and pathophysiological values of CBF, tight junction paracellular pore radius (para\textsubscript{radius}), brain\textsubscript{ECF} volume, pH\textsubscript{ECF}, and pH\textsubscript{ICF}. Para\textsubscript{radius} affected the rate and extent of passive drug transport across the BBB, pH\textsubscript{ECF} and pH\textsubscript{ICF} affected the brain\textsubscript{ECF} and brain\textsubscript{ICF} unbound drug concentration-time profile (PK), whereas cerebral blood flow and brain\textsubscript{ECF} volume had a very modest (if any) effect. The fixed plasma PK used excludes the involvement of plasma PK in the observed changes.
Figure 3. Heatmaps summarizing the effect of pathophysiological changes of CBF, tight junction paracellular pore radius (para-radius), brain ECF volume, pH_{ECD}, and pH_{ICF} on brain pharmacokinetic parameters: C_{max}, T_{max}, AUC, K_{pu, ECF}, and K_{pu, cell}. C_{max} and T_{max} define the rate of BBB drug transport, while AUC and K_{pu} define the extent of drug transport. Effect of pathophysiological changes remain drug (class) specific. Similar to the concentration–time profiles, para-radius, pH_{ECD}, and pH_{ICF} had a profound effect on brain pharmacokinetics compared to the minor effect of cerebral blood flow and brain ECF volume. The fixed plasma PK used excludes the involvement of plasma PK in the observed changes.
4. Discussion

LeiCNS-PK3.0 simulations have demonstrated the drug-dependent effect of pathophysiological changes of para\textsubscript{radius} on the rate and extent of BBB passive drug transport, and of pH\textsubscript{ECF} and pH\textsubscript{ICF} on the PK of brain\textsubscript{ECF} and brain\textsubscript{ICF}.

LeiCNS-PK3.0 allows the prediction of PK in the less accessible brain tissue and the potential PK changes associated with diseased conditions. LeiCNS-PK3.0 predictions are based explicitly on human CNS physiological parameters available from the literature, drug physicochemical parameters available from Drugbank database [26], and translated data from in vitro and preclinical studies. Thus, LeiCNS-PK3.0 overcomes the technical and ethical limitations of experimental approaches, such as the invasiveness of microdialysis, inability to differentiate parent drug and metabolite with imaging techniques, and the inaccurate lumbar CSF surrogacy to brain PK [12,102].

Paracellular passive diffusion across the BBB tight junction pores is especially critical for small, hydrophilic drugs, whose transport across the lipophilic membranes of BBB endothelial cells is limited, although this paracellular route represents about 0.004% of BBB surface area [12]. Increased passive transport via this route has been reported after BBB opening with hyperosmotic mannitol, where the brain exposure of atenolol [43] and methotrexate [103] increased by about 3- and 5-folds, respectively. BBB opening and widening of para\textsubscript{radius} after hyperosmotic mannitol were confirmed in the latter study using electron microscopy [103]. In CNS diseases, BBB permeability to drug transport across the paracellular route increases (Table 3). The impact of increased para\textsubscript{radius} on passive transport across the BBB is rather dependent on the balance between passive transcellular and passive paracellular drug transport, the difference in pH between the compartments, and the contribution of active transporters to influx or efflux BBB transport (Table 2 and Table S1 in Supplementary Materials). An increase of passive paracellular transport will generally result in Kp\textsubscript{uu,BBB} closer to unity [1]. Drugs that are heavily reliant on the transcellular route or on active transport are less sensitive to changes in para\textsubscript{radius}.

Drug physicochemical properties might also play a role, as the three drugs, whose BBB transport extent was affected, were lipophilic bases.

PH changes are relevant for drugs with $p$ka $< 9$ and/or $p$kb $> 3$, which ionize at the physiological pH range of 5–7.4, as the ionized drug species do not cross the transcellular route or cell membrane as assumed in LeiCNS-PK3.0 and are thus trapped in brain\textsubscript{ECF} and lysosomes or can escape brain\textsubscript{ECF} via the paracellular route and with ECF bulk flow [12]. A consequence of the trapping assumption is that the difference in pH across a membrane will result in unequal drug partitioning across the membrane. This phenomena has been overlooked in several studies where changes in brain\textsubscript{ECF} PK due to traumatic brain injury were attributed to a reduction of active transport [5,10] and increase para\textsubscript{radius} [5,10,104], but not to pH\textsubscript{ECF}. The results of our simulation strongly suggest that pH changes in CNS disease might play a bigger role in defining disease brain PK than previously conceived.

The impact on brain PK due to changes in para\textsubscript{radius}, pH\textsubscript{ECF}, and pH\textsubscript{ICF} during traumatic brain injury (TBI), Alzheimer’s disease (AD), brain malignancies, cerebral ischemia, and epilepsy has been explored, as guided by LeiCNS-PK3.0 simulations. The pathophysiological changes of the three parameters in these CNS diseases are listed in Table 3. Quantitative information on para\textsubscript{radius} values in the different diseases are not always reported, and therefore, BBB permeability as an indirect measure of para\textsubscript{radius} was used.

Microdialysis studies in TBI patients have shown that brain\textsubscript{ECF} PK is different in the healthy versus injured brain tissue. In two independent studies, morphine PK was higher in the injured than in the healthy brain tissue of adult [104] and pediatric TBI patients [4]. In addition, cyclosporine brain\textsubscript{ECF} PK might change in TBI patients [105]. In TBI patients, changes occur to pH\textsubscript{ICF}, pH\textsubscript{ECF}, and to para\textsubscript{radius}; the magnitude of change and time course of these parameters may differ according to trauma type: focal vs. diffuse TBI or close-head vs. open-head injury. In TBI patients, pH\textsubscript{ECF} and pH\textsubscript{ICF} decline to 7 [22] and 6.9 [106], respectively. PH measurements in TBI mice suggest a biphasic change of pH, which resolves after two hours, while in TBI patients, pH showed
a resolution to normal values after about 10 days [22,106]. PHICF changes are of minor impact on traumatic brain PK. However, pHECF changes due to TBI might impact brain PK of drugs with pk_a < 8 and pk_b > 6, respectively. The BBB opening is another feature of TBI, as evidenced by the decrease in tight junction protein expression mainly claudin-5, occludin, and ZO-1 and an increase in BBB permeability to small and medium (0.1–10 kDa) and large molecules (up to 160 kDa) [107–109] in TBI mice. BBB opening and increased permeability resides up to the first 96 and 24 h post-injury for small and large molecules, respectively [107–109]. A wide range of CNS-acting medications are used to manage TBI patients including analgesics (e.g., acetaminophen, morphine), anticonvulsants (e.g., gabapentin and carbamazepin), neuroprotective agents (e.g., cyclosporine), etc. LeiCNS-PK3.0 simulations at altered para_radius and pHECF/ICF have shown that the CNS PK of some of these drugs are potentially affected by these changes. An increase in para_radius resulted in an increase in brainECF C_max of morphine. Changes in pHECF/ICF might affect the PK of morphine (pkb = 9.1) and gabapentin (pk_a = 4.6, pk_b = 9.9). Combining the simulation results and literature findings on TBI pathophysiology and in vivo TBI PK suggests that brain PK may change due to pH and para_radius, particularly during the first 48 h after the injury.

Brain PK is potentially altered in epilepsy. Brain PK of phenytoin was lower in epileptic compared to control rats; the difference was accounted for by the increased p-gp expression in epileptic rats [110]. Brain PK of phenytoin increased following a seizure when p-gp expression was suppressed with nimodipine, implying a potential role of the BBB opening in altering phenytoin PK. Postmortem studies in rats and humans have demonstrated an increased BBB permeability to albumin and Evan’s blue (Mwt = 69 kDa) following an epileptic seizure [111], which persisted in rats up to 1 week after the seizure [111]. Epileptic seizures result as well in a decrease in pHECF by 0.5 units, which returns to normal values at a slower rate than pHICF, which declines by about 0.3 pH units and is corrected within 20 min following seizure [112]. These changes in pH are expected to impact drugs with pk_a < 8 and pk_b > 6, respectively. Our simulations included antiepileptic drugs such as phenytoin, diazepam, carbamazepine, levetiracetam, and gabapentin. Of these drugs, only levetiracetam was sensitive to changes in para_radius, while gabapentin (a zwitterion, pk_a = 4.6 and pk_b = 9.9) PK in brainICF was sensitive to changes in pHECF. Phenytoin PK changes remains interesting, as despite experimental evidence of the importance of the passive transport route [110], LeiCNS-PK3.0 simulations showed no sensitivity to para_radius changes. It is worth mentioning that in vitro studies using human- and mouse-derived p-gp have concluded that phenytoin is actively transported in rodents but not in humans [113].

Glioma patients and sarcoma-laden rats showed higher methotrexate brainECF PK compared to controls [7]. Cyclophosphamide brainECF PK, on the contrary, was lower in tumor-bearing vs. non-tumor-bearing mice [31]. Brain tumors affect BBB permeability as demonstrated by the 8-fold increase in para_radius in rats with a malignant glioma [114], which was measured with gadolinium-labeled nanoparticles of increasing size. In addition, the pHECF-to-pHICF ratio is reversed in brain tumors, as pHECF decreases to 6.7, whereas pHICF increases to 7.3 [115,116]. This will result in the change in PK and drug partitioning between brainECF and brainICF [100], which is indicated by our Kp_{w,cel} values (Figure 3 and Supplementary Figure S3), particularly for drugs with acidic and basic groups of pk_a and pk_b of <8 and >6, respectively. LeiCNS-PK3.0 simulations of the chemotherapeutic drugs, cyclophosphamide and methotrexate, showed a decline of T_max due to increased para_radius, while only methotrexate (pk_a = 3.4) PK at brainECF and brainICF PK was sensitive to pHECF and pHICF changes.
Table 3. Pathophysiological changes of para\textsubscript{radius}, pH\textsubscript{ECF}, and pH\textsubscript{ICF} in multiple CNS diseases.

| Disease | Parameter | Value | References |
|---------|-----------|-------|------------|
| Alzheimer’s | BBB permeability | ↔ (86–150,000 Da) | [107] |
| | pH\textsubscript{ECF} | ↓ (0.01 pH unit/decade) | [25] |
| | pH\textsubscript{ICF} | | |
| Brain tumors | para\textsubscript{radius} | ↑ (800%) | [114] |
| | pH\textsubscript{ECF} | ↓ (0.6 pH unit) | [115,116] |
| | pH\textsubscript{ICF} | ↑ (0.3 pH unit) | [115,116] |
| TBI | BBB permeability | ↑ (up to 160,000 Da) | [107–109] |
| | pH\textsubscript{ECF} | ↓ (0.3 pH unit) | [22] |
| | pH\textsubscript{ICF} | ↓ (0.1 pH unit) | [106] |
| Ischemia | BBB permeability | ↑ (up to 70,000 Da) | [117] |
| | pH\textsubscript{ECF} | ↓ (1.4 pH unit) | [118] |
| | pH\textsubscript{ICF} | ↓ (2 pH unit) | [23,24,119] |
| Epilepsy | BBB permeability | ↑ (albumin and up to 70,000 Da) | [111] |
| | pH\textsubscript{ECF} | ↓ (0.5 pH unit) | [112] |
| | pH\textsubscript{ICF} | ↓ (0.3 pH unit) | [112] |

Profound changes in para\textsubscript{radius} and pH\textsubscript{ECF/ICF} during cerebral ischemia suggest a change in ischemic brain PK; however, evidence of such changes are not available in the literature. The BBB permeability of gadolinium (M\textsubscript{wt} = 590 Da) and Evan’s blue increased in a rat model of cerebral ischemia–reperfusion injury, and this increase resided for 4 weeks for gadolinium and for 3 weeks for Evan’s blue [117]. In addition, cerebral ischemia is associated with a 4-h severe brain acidosis, where the pH\textsubscript{ECF} declines to 5.9 [118], while pH\textsubscript{ICF} declines to 5 [23,24,119]. This drastic pH change will result in altering the PK of both acidic (pka < 8) and basic (pka > 4) drugs.

Disease translation pharmacokinetic modeling is crucial for accurate predictions of drug effect, but it is challenging particularly for CNS diseases that are progressive, with yet unraveled pathophysiology mechanisms and scarce (pre)clinical data for model validation, not mentioning the ethical concerns in this sensitive yet critical research field. Thus, predicting a disease-specific PK at brain target sites requires a holistic approach such as PBPK modeling that accounts for both drug and (patho)physiology. In this manuscript, we applied our CNS PBPK model, LeiCNS-PK3.0, to predict the impact of altering one CNS parameter at a time on brain PK. LeiCNS-PK3.0 can also be used to predict a disease-specific PK in different regions of the CNS. This will require accounting for all disease-specific pathophysiological changes such as changes in tissue composition and non-specific binding [120], tissue volumes [121], active transporter expression and functionality [38], pH changes, CSF-related changes [12], etc. and their time course, i.e., deteriorating vs. healing. Such information is not always available from humans, and therefore, translating information on CNS pathophysiology from preclinical species is indispensable. Plasma PK acts as input to LeiCNS-PK3.0, and therefore, having the right plasma model from the disease population of interest is a crucial step to accurate CNS PK predictions. Plasma PK might change in CNS diseases compared to a healthy situation due to drug–drug interactions associated with concomitant drug administrations or due to declining liver and kidney functions as seen in elderly and AD patients.

5. Conclusions

With LeiCNS-PK3.0 simulations of CNS disease pathophysiology, we demonstrated that the BBB opening might increase the rate and extent of BBB passive transport and that a
change of pH_{ECF} and pH_{ICF} can result in altered distribution of unbound drug in brain_{ECF} and brain_{ICF}. The impact of those parameters on CNS PK should not be underestimated. It should be noted that our study conclusions remain limited to small drug molecules and may not extend to other drug classes as biologics.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/1999-4923/13/1/95/s1, Figure S1. Detailed mathematical structure of LeiCNS-PK3.0; Figure S2. Simulated concentration–time profiles of all 46 drugs at physiological and pathophysiological values of CBF, para_{radius}, brain_{ECF} volume, pH_{ECF}, and pH_{ICF}; Figure S3. Heatmaps summarizing the effect of pathophysiological changes of CBF, para_{radius}, brain_{ECF} volume, pH_{ECF}, and pH_{ICF} on brain pharmacokinetics parameters: C_{max}, T_{max}, AUC, K_{Pulse,ECF}, and K_{Pulse,cell}; Table S1. Physicochemical properties and active transporter affinity of all 46 drugs; Table S2. Mean protein expression levels (in fmol/µg total protein) of relevant transporters at the BBB.

**Author Contributions:** Conceptualization, M.A.A.S. and E.C.M.d.L.; methodology, M.A.A.S. and E.C.M.d.L.; formal analysis, M.A.A.S. and E.C.M.d.L.; investigation, M.A.A.S. and E.C.M.d.L.; writing—original draft preparation, M.A.A.S.; writing—review and editing, M.A.A.S. and E.C.M.d.L.; visualization, M.A.A.S.; supervision, E.C.M.d.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Hammarlund-Udenaes, M.; Fridén, M.; Syvänen, S.; Gupta, A. On the rate and extent of drug delivery to the brain. *Pharm. Res.* 2008, 25, 1737–1750. [CrossRef] [PubMed]
2. De Lange, E.C.M. The Physiological Characteristics and Transcytosis Mechanisms of the Blood-Brain Barrier (BBB). *Curr. Pharm. Biotechnol.* 2012, 13, 2319–2327. [CrossRef] [PubMed]
3. Loryan, I.; Sinha, V.; Mackie, C.; Van Peer, A.; Drinkenburg, W.H.; Vermeulen, A.; Heald, D.; Hammarlund-Udenaes, M.; Wassvik, C.M. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates. *Mol. Pharm.* 2015, 12, 520–532. [CrossRef] [PubMed]
4. Ketharanathan, N.; Yamamoto, Y.; Rohlwink, U.K.; Wildschut, E.D.; Mathôt, R.A.A.; De Lange, E.C.M.; De Wildt, S.N.; Argent, A.C.; Tibboel, D.; Figaji, A.A. Combining Brain Microdialysis and Translational Pharmacokinetic Modeling to Predict Drug Concentrations in Pediatric Severe Traumatic Brain Injury: The Next Step Toward Evidence-Based Pharmacotherapy? *J. Neurotrauma* 2019, 36, 111–117. [CrossRef]
5. Bouw, R.; Ederoth, P.; Lundberg, J.; Ungerstedt, U.; Nordström, C.-H.; Hammarlund-Udenaes, M. Increased blood–brain barrier permeability of morphine in a patient with severe brain lesions as determined by microdialysis. *Acta Anaesthesiol. Scand.* 2001, 45, 390–392. [CrossRef]
6. Löschner, W.; Potschka, H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. *NeuroRx* 2005, 2, 86–98. [CrossRef]
7. Westerhout, J.; Van Den Berg, D.; Hartman, R.; Danhof, M.; De Lange, E.C.M. Prediction of methotrexate CNS distribution in different species—Influence of disease conditions. *Eur. J. Pharm. Sci.* 2014, 57, 11–24. [CrossRef]
8. Castaneda-Hernandez, G.; Hoyo-Vadillo, C.; Herrera, J.E. Differences in nifedipine concentration–effect relationship between different species and slow release tablet administration. *Int. J. Clin. Pharmacol. Ther.* 1995, 33, 56–60.
9. Kuepfer, L.; Niederalt, C.; Wendl, T.; Schlierer, J.F.; Willmann, S.; Lippert, J.; Block, M.; Eissing, T.; Teutonico, D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. *CPT Pharmacomet. Syst. Pharmacol.* 2016, 5, 516–531. [CrossRef]
10. Yamamoto, Y.; Valitavo, P.A.; Wong, Y.C.; Huntjens, D.R.; Proost, J.H.; Vermeulen, A.; Krauwinkel, W.; Beukers, M.W.; Kokki, H.; Kokki, M.; et al. Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach. *Eur. J. Pharm. Sci.* 2018, 112, 168–179. [CrossRef]
11. Westerhout, J.; Ploeger, B.; Smeets, J.; Danhof, M.; De Lange, E.C.M. Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. *AAPS J.* 2012, 14, 543–553. [CrossRef] [PubMed]
12. Saleh, M.A.A.; Loo, C.F.; Elassais-Schaap, J.; De Lange, E.C.M. Lumbar cerebrospinal fluid-to-Brain extracellular fluid surrogacy is context-specific: Insights from LeiCNS-PK3.0 simulations. *J. Pharmacokinet Pharmacodyn.* Under review.
13. Yamamoto, Y.; Välitalo, P.; Huntjens, D.; Proost, J.; Vermeulen, A.; Krauwinkel, W.; Beukers, M.; van den Berg, D.; Hartman, R.; Wong, Y.; et al. Predicting drug concentration-time profiles in multiple relevant CNS compartments using a comprehensive physiologically-based pharmacokinetic model. CPT Pharmacomet. Syst. Pharmacol. 2017, 6, 765–777. [CrossRef] [PubMed]

14. Jessen, N.A.; Munk, A.S.F.; Lundgaard, I.; Nedergaard, M. The Glymphatic System: A Beginner’s Guide. Neurochem. Res. 2015, 40, 2583–2599. [CrossRef] [PubMed]

15. Syková, E. The extracellular space in the CNS: Its regulation, volume and geometry in normal and pathological neuronal function. Neuroscientist 1997, 3, 28–41. [CrossRef]

16. Yamazaki, Y.; Shinozara, M.; Shinozara, M.; Yamazaki, A.; Murray, M.E.; Liesinger, A.M.; Heckman, M.G.; Lesser, E.R.; Parisi, J.E.; Petersen, R.C.; et al. Selective loss of cortical endothelial tight junction proteins during Alzheimer’s disease progression. Brain 2019, 142, 1077–1092. [CrossRef] [PubMed]

17. Costea, L.; Mészáros; Bauer, H.; Bauer, H.C.; Traweger, A.; Wilhelm, I.; Farkas, A.E.; Krizbai, I.A. The blood–brain barrier and its intercellular junctions in age-related brain disorders. Int. J. Mol. Sci. 2019, 20, 5472. [CrossRef]

18. Logsdon, A.F.; Meabon, J.S.; Cline, M.M.; Bullock, K.M.; Raskind, M.A.; Peskind, E.R.; Banks, W.A.; Cook, D.G. Blast exposure elicits blood–brain barrier disruption and repair mediated by tight junction integrity and nitric oxide dependent processes. Sci. Rep. 2018, 8, 1–13. [CrossRef]

19. Roher, A.E.; Debbins, J.P.; Malek-Ahmad, M.; Chen, K.; Pipe, J.G.; Maze, S.; Belden, C.; Maarouf, C.L.; Thiyyagura, P.; Mo, H.; et al. Cerebral blood flow in Alzheimer’s disease. Vasc. Health Risk Manag. 2012, 8, 599–611. [CrossRef]

20. van Es, A.C.G.M.; van der Grond, J.; ten Dam, V.H.; de Craen, A.J.M.; Blauw, G.J.; Westendorp, R.G.J.; Admiraal-Behlouf, F.; van Buchem, M.A. Associations between total cerebral blood flow and age related changes of the brain. PLoS ONE 2010, 5, e9825. [CrossRef]

21. Laitio, R.M.; Kaisti, K.K.; Langsjö, J.W.; Aalto, S.; Salmi, E.; Maksimow, A.; Aantaa, R.; Oikonen, V.; Sipila, H.; Parkkola, R.; et al. Effects of xenon anesthesia on cerebral blood flow in neurosurgical humans. Anesthesiology 2007, 106, 1128–1133. [CrossRef] [PubMed]

22. Gupta, A.K.; Zygun, D.A.; Johnston, A.J.; Steiner, L.A.; Al-rawi, P.G.; Chatfield, D.O.T.; Shepherd, E.; Kirkpatrick, P.J.; Hutchinson, P.J.; Menon, D.K. Extracellular Brain pH and Outcome following Severe Traumatic Brain Injury. J. Neurotrauma 2004, 21, 678–684. [CrossRef] [PubMed]

23. Remzso, G.; Németh, J.; Varga, V.; Kovács, V.; Tóthszuki, V.; Kaila, K.; Voipio, J.; Domoki, F. Brain interstitial pH changes in the subacute phase of hypoxic-ischemic encephalopathy in newborn pigs. PLoS ONE 2020, 15, e0240643. [CrossRef]

24. Rehncrona, S. Brain acidosis. Ann. Emerg. Med. 1985, 14, 770–776. [CrossRef]

25. Lyros, E.; Ragoschke-Schumm, A.; Kostopoulos, P.; Sehr, A.; Backens, M.; Kalampokini, S.; Decker, Y.; Lesmeister, M.; Liu, Y.; Reith, W.; et al. Normal brain aging and Alzheimer’s disease are associated with lower cerebral pH: An in vivo histidine 1H-MR spectroscopy study. Neurobiol. Aging 2020, 87, 60–69. [CrossRef] [PubMed]

26. Wishart, D.S.; Feunang, Y.D.; Guo, A.C.; Lo, E.; Marcu, A.; Grant, J.R.; Sajed, T.; Johnson, D.; Li, C.; Sayeeda, Z.; et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 2017, 46, D1074–D1082. [CrossRef] [PubMed]

27. Manchester, J.; Walkup, G.; Rivin, O.; You, Z. Evaluation of pka Estimation Methods on 211 Druglike Compounds. J. Chem. Inf. Model. 2010, 50, 565–571. [CrossRef]

28. Mannhold, R.; Poda, G.I.; Ostermann, C.; Tetko, I.V. Calculation of Molecular Lipophilicity: State-of-the-Art and Comparison of LogP Methods on More Than 96,000 Compounds. J. Pharm. Sci. 2009, 98, 861–893. [CrossRef]

29. Summerfield, S.G.; Read, K.; Begley, D.J.; Obrodovic, T.; Hidalgo, I.J.; Coggson, S.; Lewis, A.V.; Porter, R.A.; Jeffrey, P. Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction. J. Pharmacol. Exp. Ther. 2007, 322, 205–213. [CrossRef]

30. Nagaya, Y.; Nozaki, Y.; Takenaka, O.; Watari, R.; Kusano, K.; Yoshimura, T.; Kusuhara, H. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(−/−) rats. Drug Metab. Pharmacokinet. 2016, 31, 57–66. [CrossRef]

31. Campagne, O.; Davis, A.; Zhong, B.; Nair, S.; Haberman, V.; Patel, Y.T.; Janke, L.; Roussel, M.F.; Stewart, C.F. CNS Penetration of Cyclophosphamide and Metabolites in Mice Bearing Group 3 Medulloblastoma and Non-tumor Bearing Mice. J. Pharm. Pharm. Sci. 2019, 22, 612–629. [CrossRef] [PubMed]

32. Al-Majdoub, Z.M.; Al Feteisi, H.; Achour, B.; Warwood, S.; Neuhoff, S.; Rostami-Hodjegan, A.; Barber, J. Proteomic Quantification of Human Blood–Brain Barrier Transporters in Healthy Individuals and Dementia Patients. Mol. Pharm. 2019. [CrossRef] [PubMed]

33. Al Feteisi, H.; Al-Majdoub, Z.M.; Achour, B.; Couto, N.; Rostami-Hodjegan, A.; Barber, J. Identification and quantification of blood–brain barrier transporters in isolated rat brain microvessels. J. Neurochem. 2018, 146, 670–685. [CrossRef]

34. Uchida, Y.; Ohtsuki, S.; Katsukura, Y.; Ikeda, C.; Suzuki, T.; Kamiie, J.; Terasaki, T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 2011, 117, 333–345. [CrossRef] [PubMed]

35. Hoshi, Y.; Uchida, Y.; Tachikawa, M.; Inoue, T.; Ohtsuki, S.; Terasaki, T. Quantitative Atlas of Blood–Brain Barrier Transporters, Receptors, and Tight Junction Proteins in Rats and Common Marmoset. J. Pharm. Sci. 2013, 102, 3343–3355. [CrossRef]

36. Shawahna, R.; Uchida, Y.; Declèves, X.; Ohtsuki, S.; Yousif, S.; Daunchy, S.; Jacob, A.; Chassoux, F.; Daumas-Dupont, C.; Couraud, P.O.; et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm. 2011, 8, 1332–1341. [CrossRef]
37. Kodaira, H.; Kusuhara, H.; Fuse, E.; Ushiki, J.; Sugiyama, Y. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters. *Drug Metab. Dispos.* 2014, 42, 983–989. [CrossRef]

38. De Lange, E.C.M.; vd Berg, D.J.; Bellanti, F.; Voskuyl, R.A.; Svyān, S. P-glycoprotein protein expression versus functionality at the blood-brain barrier using immunohistochemistry, microdialysis and mathematical modeling. *Eur. J. Pharm. Sci.* 2018, 124, 61–70. [CrossRef]

39. Chu, X.; Bleasby, K.; Evers, R. Species differences in drug transporters and implications for translating preclinical findings to humans. *Expert Opin. Drug Metab. Toxicol.* 2013, 9, 237–252. [CrossRef]

40. Li, M.; Yuan, H.; Li, N.; Song, G.; Zheng, Y.; Baratta, M.; Hua, F.; Thurston, A.; Wang, J.; Lai, Y. Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. *Eur. J. Pharm. Sci.* 2008, 35, 114–126. [CrossRef]

41. Booth-Genthe, C.L.; Louie, S.W.; Carlini, E.J.; Li, B.; Leake, B.F.; Eisenhandler, R.; Hochman, J.H.; Mei, Q.; Kim, R.B.; Rushmore, T.H.; et al. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): Comparison of rat P-glycoprotein transport to human and mouse. *J. Pharmacol. Toxicol. Methods* 2006, 54, 78–89. [CrossRef] [PubMed]

42. Nordström, C.H.; Koskinen, L.O.; Olivecrona, M. Aspects on the physiological and biochemical foundations of neurocritical care. *Front. Neurol.* 2017, 8, 1–24. [CrossRef] [PubMed]

43. De Lange, E.C.M.; Hesselink, M.B.; Danhof, M.; de Boer, A.G.; Breimer, D.D. The Use of Intracerebral Microdialysis to Determine Changes in Blood-Brain Barrier Transport Characteristics. *Pharm. Res.* 1995, 12, 129–133. [CrossRef] [PubMed]

44. Arieff, A.I.; Kerian, A.; Massry, S.G.; DeLima, J. Intracellular pH of brain: Alterations in acute respiratory acidosis and alkalosis. *Am. J. Physiol.* 1976, 230, 804–812. [CrossRef]

45. Filipek, P.A.; Richelme, C.; Kennedy, D.N.; Caviness, V.S. The Young Adult Human Brain: An MRI-based Morphometric Analysis. *J. Cell Biol.* 1994, 124, 346–360. [CrossRef] [PubMed]

46. Gur, R.C.; Mozley, P.D.; Resnick, S.M.; Gottlieb, D.; Zee, S.K.; Herman, G.T.; Atlas, S.; Grossman, R.; Berretta, D. Gender differences in age effect on brain atrophy measured by magnetic resonance imaging. *Proc. Natl. Acad. Sci. USA* 1991, 88, 2845–2849. [CrossRef]

47. Courchesne, E.; Chisum, H.J.; Townsend, J.; Cowles, A.; Covington, J.; Egaas, B.; Harwood, M.; Hinds, S.; Press, G.A. Normal Brain Development and Aging: Quantitative Analysis at in Vivo MR Imaging in Healthy Volunteers. *Radiology* 2000, 216, 672–682. [CrossRef]

48. Filipek, P.A.; Richelme, C.; Kennedy, D.N.; Caviness, V.S. The Young Adult Human Brain: An MRI-based Morphometric Analysis. *Cereb. Cortex* 1994, 4, 344–360. [CrossRef]

49. Gur, R.C.; Mozley, P.D.; Resnick, S.M.; Gottlieb, D.; Zee, S.K.; Herman, G.T.; Atlas, S.; Grossman, R.; Berretta, D. Gender differences in age effect on brain atrophy measured by magnetic resonance imaging. *Proc. Natl. Acad. Sci. USA* 1991, 88, 2845–2849. [CrossRef]

50. Peters, M.; Jäncke, L.; Stager, J.F.; Schlaga, G.; Huang, Y.; Steinmetz, H. Unsolved Problems in Comparing Brain Sizes in Homo Sapiens. *Brain Cogn.* 1998, 37, 254–285. [CrossRef]

51. Lei, Y.; Han, H.; Yuan, F.; Javeed, A.; Zhao, Y. The brain interstitial system: Anatomy, modeling, in vivo measurement, and applications. *Prog. Neurobiol.* 2017, 157, 230–246. [CrossRef]

52. Miyajima, M.; Arai, H. Evaluation of the Production and Absorption of Cerebrospinal Fluid. *Neurol. Med. Chir. (Tokyo)* 2015, 55, 647–656. [CrossRef]

53. Nicholson, C. Diffusion and related transport mechanisms in brain tissue. *Rep. Prog. Phys.* 2001, 64, 815–884. [CrossRef]

54. Nicholson, C.; Kamali-Zare, P.; Tao, L. Brain Extracellular Space as a Diffusion Barrier. *Comput. Vis. Sci.* 2011, 14, 309–325. [CrossRef] [PubMed]

55. Thorne, R.G.; Hrabˇetová, S.; Nicholson, C. Diffusion of Epidermal Growth Factor in Rat Brain Extracellular Space Measured by Integrative Optical Imaging. *J. Neurophysiol.* 2004, 92, 3471–3481. [CrossRef] [PubMed]

56. Weibel, E.R.; Staubli, W.; Gnägi, H.R.; Hess, F.A. Correlated Morphometric and Biochemical Studies on the Liver Cell: I. Morphometric Model, Stereologic Methods, and Normal Morphometric Data for Rat Liver. *J. Cell Biol.* 1969, 42, 68–91. [CrossRef] [PubMed]

57. Brown, R.P.; Delp, M.D.; Lindstedt, S.L.; Romhberg, L.R.; Bellies, R.P. Physiological Parameter Values for Physiologically Based Pharmacokinetic Models. *Toxicol. Ind. Health* 1997, 13, 407–484. [CrossRef]

58. Hu, Z.-Y.; Lu, J.; Zhao, Y. A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. *Br. J. Pharmacol.* 2014, 171, 2778–2789. [CrossRef]

59. Allen, J.S.; Damasio, H.; Grabowski, T.J. Normal neuroanatomical variation in the human brain: An MRI-volumetric study. *Am. J. Phys. Anthropol.* 2002, 118, 341–358. [CrossRef]

60. Barra, V.; Frenoux, E.; Boire, J.-Y. Automatic volumetric measurement of lateral ventricles on magnetic resonance images with correction of partial volume effects. *J. Magn. Reson. Imaging* 2002, 15, 16–22. [CrossRef]

61. Erdogan, A.L.I.R.; Dane, S.; Aydin, M.D.; Özüdik, M.; Diyarbakırli, S. Sex and Handedness Differences in Size of Cerebral Ventriles of Normal Subjects. *Int. J. Neurosci.* 2004, 114, 67–73. [CrossRef]

62. Lamers, M.; Klein, W.; Göraj, B. Normal Values of Ventricular Volume and Cerebrospinal Fluid (CSF) Circulation in Healthy Subjects. Available online: https://posterg.netkey.at/esr/viewing/index.php?module=viewing_poster&doi=10.1594/ecr2010/C-2729 (accessed on 1 November 2020).
94. Cornford, M.E.; Landaw, E.M.; Hyman, S.; Cornford, E.M.; Delgado-Escueta, A.V. Interictal Seizure Resections Show Two Configurations of Endothelial Glut1 Glucose Transporter in the Human Blood–Brain Barrier. J. Cereb. Blood Flow Metab. 1998, 18, 26–42. [CrossRef] [PubMed]

95. Sarin, H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J. Angiogenes. Res. 2010, 2, 14. [CrossRef]

96. Monteiro, J.N.; Goraksha, S.U. *ROSE concept* of fluid management: Relevance in neuroanaesthesia and neurocritical care. J. Neuroanaesth. Crit. Care 2017, 4, 10–16. [CrossRef]

97. Haas, T.L.; Duling, B.R. Morphology Favors an Endothelial Cell Pathway for Longitudinal Conduction within Arterioles. Microvasc. Res. 1997, 53, 113–120. [CrossRef]

98. Schulze, C.; Firth, J.A. Interendothelial junctions during blood-brain barrier development in the rat: Morphological changes at the level of individual tight junctional contacts. Dev. Brain Res. 1992, 69, 85–95. [CrossRef]

99. Atherton, J.C. Acid-base balance: Maintenance of plasma pH. Anaesth. Intensive Care Med. 2008, 6, 353–359. [CrossRef] [PubMed]

100. Frid, N.; Bäckström, S.; Berndt, S.; Jourdain, S.; Sjöblom, M.; Sjöblom, T.; Shorey, S.; Wachtenheim, S.; Westerberg, A.; Zettervall, K.; et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J. Cereb. Blood Flow Metab. 2010, 31, 256–265. [CrossRef] [PubMed]

101. Siesjo, B.K.; von Hanwehr, R.; Nergelius, G.; Nevander, G.; Ingvar, M. Extra- and intracellular pH in the brain during seizures. Acta Neurochir. 1997, 139, 481–484. [CrossRef]

102. De Lange, E.C.M. Utility of CSF in translational neuroscience. J. Pharmacokin. Pharmacodyn. 2013, 40, 315–326. [CrossRef] [PubMed]

103. Cosolo, W.C.; Martinello, P.; Louis, W.J.; Christophidis, N. Blood-brain barrier disruption using mannitol: Time course and electron microscopy studies. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1989, 256, 443–447. [CrossRef]

104. Ederoth, P.; Tunblad, K.; Bouw, R.; Lundberg, C.J.F.; Ungerstedt, U.; Nordström, C.H.; Hammarlund-Udenaes, M. Blood-brain barrier transport of morphine in patients with severe brain trauma. Br. J. Clin. Pharmacol. 2004, 57, 427–435. [CrossRef] [PubMed]

105. Brophy, G.M.; Mazzeo, A.T.; Brar, S.; Alves, O.L.; Bunnell, K.; Gilman, C.; Karnes, T.; Hayes, R.L.; Bullock, R. Exposure of Cyclosporin A in Whole Blood, Cerebral Spinal Fluid, and Brain Extracellular Fluid Dialysate in Adults with Traumatic Brain Injury. J. Neurotrauma 2013, 30, 1484–1498. [CrossRef]

106. Vink, R.; McIntosh, T.K.; Weiner, M.W.; Faden, A.I. Effects of traumatic brain injury on cerebral high-energy phosphates and pH: A 31P magnetic resonance spectroscopy study. J. Cereb. Blood Flow Metab. 1987, 7, 563–571. [CrossRef]

107. Lochhead, J.J.; Yang, J.; Ronaldson, P.T.; Davis, T.P. Structure, Function, and Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders. Front. Physiol. 2020, 11. [CrossRef]

108. Hue, C.D.; Cho, F.S.; Cao, S.; Nicholls, R.E.; Vogel, E.W.; Sibindi, C.; Arancio, O.; Dale Bass, C.R.; Meaney, D.F.; Morrison, B. Time Course and Size of Blood-Brain Barrier Opening in a Mouse Model of Blast-Induced Traumatic Brain Injury. J. Neurotrauma 2016, 33, 1202–1211. [CrossRef]

109. Readnower, R.D.; Chavko, M.; Adeeb, S.; Conroy, M.D.; Pauly, J.R.; McCarron, R.M.; Sullivan, P.G. Increase in Blood Brain Barrier Permeability, Oxidative Stress, and Activated Microglia in a Rat Model of Blast Induced Traumatic Brain Injury. J. Neurosci. Res. 2010, 88, 3530–3539. [CrossRef]

110. Höcht, C.; Lazarowski, A.; Gonzalez, N.N.; Auzemendi, J.; Opezzo, J.A.W.; Bramuglia, G.F.; Taira, C.A.; Girardi, E. Nimodipine restores the altered hippocampal phenytoin pharmokinetics in a refractory epileptic model. Neurosci. Lett. 2007, 413, 168–172. [CrossRef]

111. Van Vliet, E.A.; Araújo, S.D.C.; Redeker, S.; Van Schaik, R.; Aronica, E.; Gorter, J.A. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007, 130, 521–534. [CrossRef]

112. Siesjö, B.K.; von Hanwehr, R.; Neergard, G.; Nergelius, G.; Neander, G.; Ingvar, M. Extra- and intracellular pH in the brain during seizures and in the recovery period following the arrest of seizure activity. J. Cereb. Blood Flow Metab. 1985, 5, 47–57. [CrossRef] [PubMed]

113. Baltes, S.; Gastens, A.M.; Fedrowitz, M.; Potschka, H.; Kaever, V.; Löscher, W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007, 52, 333–346. [CrossRef] [PubMed]

114. Sarin, H.; Kaneyvsky, A.S.; Wu, H.; Brimacombe, K.R.; Fung, S.H.; Sousa, A.A.; Auh, S.; Wilson, C.M.; Sharma, K.; Aronova, M.A.; et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J. Transl. Med. 2008, 6, 1–15. [CrossRef]

115. Lim, H.; Albatany, M.; Martinez-Santiesteban, F.; Bartha, R.; Scholl, T.J. Longitudinal Measurements of Intra- and Extracellular pH Gradient in a Rat Model of Glioma. Tomography 2018, 4, 46–54. [CrossRef]

116. Hao, G.; Xu, Z.P.; Li, L. Manipulating extracellular tumour pH: An effective target for cancer therapy. RSC Adv. 2018, 8, 22182–22192. [CrossRef]

117. Strbian, D.; Durukan, A.; Pitkonen, M.; Marinikovic, I.; Tatlisumak, E.; Pedrono, E.; Abo-Ramadan, U.; Tatlisumak, T. The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia. Neuroscience 2008, 153, 175–181. [CrossRef]

118. Nedergaard, M.; Kraig, R.P.; Tanabe, J.; Pulselinelli, W.A. Dynamics of interstitial and intracellular pH in evolving brain infarct. Am. J. Physiol. 1991, 260, R581–R588. [CrossRef]
119. Hurn, P.D.; Traystman, R.J. pH-Associated brain injury in cerebral ischemia and circulatory arrest. *J. Intensive Care Med.* 1996, 11, 205–218. [CrossRef]

120. Gustafsson, S.; Sehlin, D.; Lampa, E.; Hammarlund-Udenaes, M.; Loryan, I. Heterogeneous drug tissue binding in brain regions of rats, Alzheimer’s patients and controls: Impact on translational drug development. *Sci. Rep.* 2019, 9, 5308. [CrossRef]

121. Fjell, A.M.; McEvoy, L.; Holland, D.; Dale, A.M.; Walhovd, K.B. Brain changes in older adults at very low risk for Alzheimer’s disease. *J. Neurosci.* 2013, 33, 8237–8242. [CrossRef] [PubMed]